Provider: Ingenta Connect
Database: Ingenta Connect
Content: application/x-research-info-systems
TY - ABST
AU - Kamalapuram, Sishir K.
AU - Kanwar, Rupinder K.
AU - Kanwar, Jagat R.
TI - Nanotheranostic Based Iron Oxide (Fe3O4) Saturated Lactoferrin Nanocapsules for Colonic Adenocarcinoma
JO - Journal of Biomedical Nanotechnology
PY - 2016-09-01T00:00:00///
VL - 12
IS - 9
SP - 1758
EP - 1773
KW - LACTOFERRIN
KW - IMAGING
KW - NANOTHERANOSTIC
KW - MULTIMODAL NANOMEDICINE
KW - ADENOCARCINOMA
KW - NANOCAPSULES
KW - IRON OXIDE
N2 - Efficient early detection of cancer and its simultaneous therapy can improve the survival of cancer patients significantly. Recently there is great interest for the development of nanotheranostic systems with multimodal live real-time imaging ability. Novel multimodal multifunctional
iron oxide (Fe3O4) saturated lactoferrin (FebLf) nanocapsules/nanocarriers (FebLf NCs) nanoformulation was fabricated. Anti-cancer nanotheranostic ability in human xenograft colonic adenocarcinoma model was conducted in vivo by employing near infrared flouroscence
(NIRF) real time live mice imaging technology. FebLf NCs showed spherical morphology with 50 to 80 nm size with super paramagnetic property and exhibited profound in vivo anti-tumour efficacy, leading to regression of the xenograft colonic tumour growth over a 90 day trial period. NIRF
real time imaging revealed selective localisation patterns of the FebLf NCs at the tumour site causing tumour growth inhibition. In turn, ex vivo NIRF imaging of mice organs showed enhanced tumoural uptake and biodistribution at the vital organs including spleen, intestine, kidney,
and intestine. Low-density lipoprotein receptors (LDLRs), ferroportin, ferritin receptor based in vivo internalisation mechanisms and iron metabolism regulation were observed. Histopathological analysis revealed obsolute non-toxic nature of FebLf NCs in mice tissues. These observations
summate biocompatible, multimodal anticancer activity of novel FebLf NCs for real time cancer therapeutic imaging leading to targeted colonic adenocarcinoma therapy.
UR - https://www.ingentaconnect.com/content/asp/jbn/2016/00000012/00000009/art00005
M3 - doi:10.1166/jbn.2016.2295
UR - https://doi.org/10.1166/jbn.2016.2295
ER -